Crizanlizumab is a monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.
- Mechanism
- Curator reviewed · 5 references
Crizanlizumab binds to P-selectin on endothelial cells and platelets, preventing their interaction with P-selectin glycoprotein ligand 1 on endothelial cells, platelets, red blood cells, and leukocytes. By preventing this interaction, components of the blood are less likely to come together, causing a vaso-occlusive crisis in patients with sickle cell diseases. The median per year incidence of vaso-occlusive crises was 1.04 in the high-dose crizanlizumab group, 2.00 in the low-dose crizanlizumab group, and 2.08 in the placebo group.
- Primary indication
- Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are ≥16 years old.Curator reviewed · 1 structured indication
- Formula / weight
- 146000.0 Da (Theoretical)
- First approval
- United States, 2019
- Also known as
- crizanlizumab-tmca
- Code names
- SEG101
- Brand names
Resolves to
What you can answer from here — as of August 16, 2023
Which drugs share a target with Crizanlizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account